May 12, 2021
Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium
May 5, 2021
Xilio Therapeutics Appoints Christina Rossi to its Board of Directors
April 12, 2021
Xilio Therapeutics Strengthens Management Team with R&D Leadership Appointments
March 29, 2021
Xilio Therapeutics Strengthens Leadership Team with the Addition of Two Executives
February 24, 2021
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
Displaying 11 - 15 of 15